Updates on the version 9

Revised Stage Group Definitions:

Stage IIB: Previously defined as T3N0M0, this stage has been reclassified to T1-T2N1M0. This change reflects a more accurate representation of prognosis where tumor size and nodal status are considered more comprehensively.

Stage IIIA: Updated from T1-T2N1M0 to T3N0-N1M0, adjusting the classification to better correlate with survival outcomes.

Stage IIIC: Modified from T3-T4N1M0 to T4N1M0, narrowing the criteria to ensure that the classification more closely aligns with the prognosis observed in patient populations.

Elimination of Stage 0: Stage 0, which represented in situ disease or high-grade squamous intraepithelial lesions (HSIL) and was not an invasive malignancy, has been removed. This adjustment prevents the over-treatment of pre-malignant conditions and aligns treatment protocols more closely with clinical significance.